DMAC DiaMedica Therapeutics Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 17 December 2019 DiaMedica Therapeutics Announces First Patient Dosed in REDUX Phase II Clinical Trial of DM199 for the Treatment of Chronic Kidney Disease

   DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biotechnology company, today announced dosing of the first patient in its REDUX Phase II study of DM199 for the treatment of Chronic Kidney Disease (CKD). This

2. 13 November 2019 DiaMedica Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

   Phase II Study of DM199 in Chronic Kidney Disease Commences Screening REMEDY Phase II Study of DM199 in Acute Ischemic Stroke Completes Enrollment Management Team Strengthens with Sydney Gilman, Ph.D., Vice

3. 06 November 2019 DiaMedica Therapeutics to Report Third Quarter 2019 Financials and Provide a Business Update November 14, 2019

   DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that its third quarter 2019 financial results will be released after the markets close on Wednesday, November 13th. DiaMedica will host a live conference call on

4. 05 November 2019 DiaMedica Therapeutics to Participate in 10th Annual Craig-Hallum Alpha Select Conference

   DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that Rick Pauls, President & Chief Executive Officer, will meet with institutional investors at the 10th Annual Craig-Hallum Alpha Select Conference on

5. 14 October 2019 DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease

   DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Phase II clinical trial protocol for the treatment of Chronic Kidney Disease (CKD).

6. 06 September 2019 DiaMedica Therapeutics to Present at Lake Street's 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019

   MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas Growth (BIG3) Conference on

7. 03 September 2019 DiaMedica Therapeutics to Present at the 2019 Dougherty & Co. Institutional Investor Conference

   MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor Conference in Minneapolis,